Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Germany”

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaActive Not Recruiting
NCT04099251Phase 3Updated Aug 7, 2026
Sponsor: Bristol-Myers Squibb
Melanoma
United States, Australia, Austria, Belgium, Canada +15 more
First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic NeoplasmsNot Yet Recruiting
NCT07752121N/AUpdated Aug 7, 2026
Sponsor: Bristol-Myers Squibb
Myelodysplastic Neoplasms
Germany
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)Recruiting
NCT06136559Phase 3Updated Aug 7, 2026
Sponsor: Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
United States, Australia, Belgium, Brazil, Canada +24 more
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)Active Not Recruiting
NCT06459180Phase 3Updated Aug 7, 2026
Sponsor: Merck Sharp & Dohme LLC
Cervical Cancer
United States, Argentina, Australia, Austria, Belgium +27 more
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With CancerRecruiting
NCT05999994Phase 2Updated Aug 7, 2026
Sponsor: Eli Lilly and Company
Neoplasms · Child · Adolescent
United States, Australia, Belgium, France, Germany +5 more
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)Recruiting
NCT07216703Phase 3Updated Aug 7, 2026
Sponsor: Merck Sharp & Dohme LLC
Cervical Cancer
United States, Argentina, Austria, Belgium, Brazil +22 more
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVDRecruiting
NCT06813911Phase 3Updated Aug 7, 2026
Sponsor: Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease (ASCVD)
United States, China, France, Germany, Hong Kong +6 more
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruiting
NCT04973605Phase 1, Phase 2Updated Aug 7, 2026
Sponsor: BeOne Medicines
Relapsed/Refractory Multiple Myeloma
United States, Australia, Brazil, Canada, China +8 more
Non-Interventional Study on the Prevalence of Cardiac Amyloidosis in Patients With Higher-Grade Aortic Valve Stenosis - Evaluation Using Echocardiography, Computed Tomography, Tc99-SPECT/CT and Cardiac Magnetic Resonance Imaging (CMR)Recruiting
NCT07752732N/AUpdated Aug 7, 2026
Sponsor: University Hospital Tuebingen
Amyloidosis Cardiac · Stenosis Coronary · TAVI(Transcatheter Aortic Valve Implantation)
Germany
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular EventsNot Yet Recruiting
NCT07474649Phase 3Updated Aug 7, 2026
Sponsor: Daiichi Sankyo
Coronary Atherosclerosis · Mixed Dyslipidemia · Hypercholesterolemia
Germany, Italy, Spain
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate CancerActive Not Recruiting
NCT04689828Phase 3Updated Aug 7, 2026
Sponsor: Novartis Pharmaceuticals
Prostatic Neoplasms
United States, Austria, Belgium, Canada, Czechia +9 more
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)Recruiting
NCT04844606Phase 3Updated Aug 7, 2026
Sponsor: Eli Lilly and Company
Ulcerative Colitis · Ulcerative Colitis Chronic · Inflammatory Bowel Diseases · Crohn's Disease
United States, Austria, Belgium, Brazil, Canada +11 more
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical SurgeryActive Not Recruiting
NCT05713838Phase 2Updated Aug 7, 2026
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Esophagus Adenocarcinoma
Germany
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruiting
NCT06890598Phase 3Updated Aug 7, 2026
Sponsor: Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
United States, Australia, Austria, Belgium, Brazil +24 more
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's DiseaseActive Not Recruiting
NCT05668013Phase 2Updated Aug 7, 2026
Sponsor: Teva Branded Pharmaceutical Products R&D LLC
Crohn Disease · Colitis, Ulcerative
United States, Austria, Bulgaria, Czechia, Georgia +11 more
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH PatientsRecruiting
NCT06934967Phase 3Updated Aug 7, 2026
Sponsor: Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria (PNH)
United States, Brazil, Colombia, Germany, Italy +1 more
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal HemoglobinuriaActive Not Recruiting
NCT04747613Phase 3Updated Aug 7, 2026
Sponsor: Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
United States, Brazil, China, Czechia, France +12 more
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsRecruiting
NCT05307705Phase 1Updated Aug 7, 2026
Sponsor: Eli Lilly and Company
Breast Cancer
United States, Australia, Belgium, Canada, China +7 more
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsRecruiting
NCT06943755Phase 2, Phase 3Updated Aug 7, 2026
Sponsor: Exelixis
Pancreatic Neuroendocrine Tumor (pNET) · Extra-Pancreatic Neuroendocrine Tumor (epNET)
United States, Australia, Austria, Belgium, Canada +10 more
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary SurgeryRecruiting
NCT07140172NAUpdated Aug 7, 2026
Sponsor: University Hospital, Basel, Switzerland
Breast Cancer
United States, Austria, Canada, Croatia, Germany +6 more
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)Recruiting
NCT06439277Phase 3Updated Aug 7, 2026
Sponsor: Eli Lilly and Company
Obesity · Weight Gain
United States, Argentina, Australia, Canada, France +7 more
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerActive Not Recruiting
NCT03706365Phase 2, Phase 3Updated Aug 7, 2026
Sponsor: Eli Lilly and Company
Prostate Cancer
United States, Australia, China, Denmark, France +6 more
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET PatientsActive Not Recruiting
NCT03049189Phase 3Updated Aug 7, 2026
Sponsor: ITM Solucin GmbH
Neuroendocrine Tumors
United States, Australia, Austria, Belgium, Czechia +9 more
Effects of Rehabilitation Combined With a Maintenance Program Compared to Rehabilitation Alone in Post-COVID-19Completed
NCT06124625NAUpdated Aug 7, 2026
Sponsor: Schön Klinik Berchtesgadener Land
Post-COVID-19 Syndrome
Germany
Pridopidine Phase 3 Study in Huntington's DiseaseRecruiting
NCT07609108Phase 3Updated Aug 7, 2026
Sponsor: Prilenia
Huntington Disease
United States, Belgium, Canada, Czechia, France +7 more

Previous page Next page